Evidence map›Paper›PMID 33496315›Full record

ArticleClinical chemistry2021

Nanopore Identification of Single Nucleotide Mutations in Circulating Tumor DNA by Multiplexed Ligation.

Nitza Burck, Tal Gilboa, Abhilash Gadi, Michelle Patkin Nehrer, Robert J Schneider, Amit Meller

Open access · hybridAbstract read
In one paragraph

Article in Clinical chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Solid-State Nanopores for Biomolecular Analysis and Detection.Advances in biochemical engineering/biotechnology · 2024
    Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Nitza BurckDepartment of Biomedical Engineering, Technion- IIT, Haifa, Israel.
Tal GilboaDepartment of Biomedical Engineering, Technion- IIT, Haifa, Israel.
Abhilash GadiDepartment of Microbiology, NYU School of Medicine, New York, NY, USA.
Michelle Patkin NehrerDepartment of Biomedical Engineering, Technion- IIT, Haifa, Israel.
Robert J SchneiderDepartment of Microbiology, NYU School of Medicine, New York, NY, USA.
Amit MellerDepartment of Biomedical Engineering, Technion- IIT, Haifa, Israel.
Technion – Israel Institute of Technology · ILNew York University · USBrigham and Women's Hospital · US

Funding

European Research Council 833399
6 · The paper itself

Abstract

backgroundCirculating tumor DNAs (ctDNAs) are highly promising cancer biomarkers, potentially applicable for noninvasive liquid biopsy and disease monitoring. However, to date, sequencing of ctDNAs has proven to be challenging primarily due to small sample size and high background of fragmented cell-free DNAs (cfDNAs) derived from normal cells in the circulation, specifically in early stage cancer.

methodsSolid-state nanopores (ssNPs) have recently emerged as a highly efficient tool for single-DNA sensing and analysis. Herein, we present a rapid nanopore genotyping strategy to enable an amplification-free identification and classification of ctDNA mutations. A biochemical ligation detection assay was used for the creation of specific fluorescently-labelled short DNA reporter molecules. Color conjugation with multiple fluorophores enabled a unique multi-color signature for different mutations, offering multiplexing potency. Single-molecule readout of the fluorescent labels was carried out by electro-optical sensing via solid-state nanopores drilled in titanium oxide membranes.

resultsAs proof of concept, we utilized our method to detect the presence of low-quantity ERBB2 F310S and PIK3Ca H1047R breast cancer mutations from both plasmids and xenograft mice blood samples. We demonstrated an ability to distinguish between a wild type and a mutated sample, and between the different mutations in the same sample.

conclusionsOur method can potentially enable rapid and low cost ctDNA analysis that completely circumvents PCR amplification and library preparation. This approach will thus meet a currently unmet demand in terms of sensitivity, multiplexing and cost, opening new avenues for early diagnosis of cancer.

Indexed as

Breast NeoplasmsCirculating Tumor DNANanoporesAnimalsBiomarkers, TumorDNA, NeoplasmFemaleHumansMiceMutationNucleotidesBiomarkers, TumorCirculating Tumor DNADNA, NeoplasmNucleotidesctDNA mutation identificationelectro-optical sensingsingle-molecule sensingsolid-state nanopore

Identifiers

PMID33496315
PMCPMC7617058
OpenAlexW3124587206

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.